GDF-15 and/or Troponin T for Predicting Kidney Failure in Heart Surgery Patients
AssigneeRoche Diagnostics Operations, Inc.
InventorsAndrea Horsch, Dietmar Zdunek, George Hess
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the field of laboratory diagnostics. Specifically, means and methods are disclosed for determining a patient's risk of suffering from acute kidney injury after a surgical procedure based on the detection of GDF-15, troponin T and/or a natriuretic peptide.
Claims14
A method for determining a patient's risk of developing acute kidney injury (AKI) during or after a surgical procedure, the method comprising the steps of:
- (a) determining the amount of a biomarker in a blood, plasma, or serum sample from the patient which has been taken before the patient undergoes the surgical procedure, wherein the biomarker comprises GDF-15 and/or Troponin;
- (b) comparing the determined amount of the biomarker with a reference amount, wherein the patient's risk of developing AKI during or after the surgical procedure is predicted.
A method for deciding whether a risk patient is eligible for a surgical procedure comprising the steps of:
- (a) determining the amount of GDF-15 and/or troponin in a sample of the patient;
- (b) comparing the determined amount with a reference amount, whereby it is decided whether the patient is eligible for the surgical procedure.
A method for predicting in a risk patient having been subjected to a surgical procedure the risk to suffer from acute kidney injury comprising the steps of:
- (a) determining the amount of GDF-15 in a sample of the patient;
- (b) comparing the determined amount with a reference amount, whereby the risk of the patient to suffer from acute kidney injury is predicted.
A device for predicting a patient's risk of developing acute kidney injury (AKI) during or after a surgical procedure, comprising:
- (a) an analyzing unit comprising means for determining the amount of a biomarker in a blood, plasma, or serum sample from the patient which has been taken before the patient undergoes the surgical procedure, wherein the biomarker comprises GDF-15 and/or Troponin;
- and
- (b) an evaluation unit comprising a computer for comparing the determined amount of biomarker with a reference amount, predicting the patient's risk of AKI during or after the surgical procedure, and providing an output indicating the risk of AKI.
Dependencies are inferred from the claim text.